The business model allows for the reduction of both cost and time. Selling or licencing treatments after Phase II greatly reduces costs and saves time. Not having to further the development in relation to marketing after Phase III also saves time and money.
Outsourcing most of the pre-clinical and clinical trails reduces overhead, this may not be specific to Regen, but still a good practice for business.
Not to mention the way patents are found, licensed, and eventually re-patented. This saves a ton of time as some treatments are not made from scratch.
News 
Market Data 
Discover 
